Targeted Therapies Are Impacting the Treatment of NETs

Nov 4, 2021

Conference|NANETS Annual Multidisciplinary NET Medical Symposium

Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses how targeted therapies are impacting the treatment of NETs.

In a Pharmacy Times® interview, Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, about her presentation on neuroendocrine tumor (NETs) management in large cancer centers at the NANETS 2021 Conference.

She discussed how targeted therapies are impacting the treatment of NETs.

Related Videos

Credit: thodonal - stock.adobe.com

Credit: Lars Neumann - stock.adobe.com

Image Credit: Adobe Stock - peterschreiber.media

Conference attendees watching a speaker | Image credit: kasto - stock.adobe.com

Biosimilars | Image credit: lexiconimages - stock.adobe.com

Medical care team | Image credit: Iryna - stock.adobe.com

Pharmacist helping patient | Image credit: Zamrznuti tonovi - stock.adobe.com

Pharmacist in home infusion environment | Image credit: Satjawat - stock.adobe.com

Related Content

Dual Bispecific Combination Study Shows 96% Overall Response Rate in Relapsed/Refractory Multiple Myeloma

Pharmacy Focus: Independent Rx Forum- What to Know for the NCPA 2022 Annual Convention

PROSPECT Trial Shows De-escalation of Rectal Cancer Treatment Can Achieve Same High Cure Rate With Less Toxicity

Pharmacy Focus: On The Shelf - Camille Schrier, 2019 and 2020 Miss America

Overall Survival of Patients With Metastatic NSCLC Sustained Up to 4 Years With Opdivo, Yervoy Combination

Durvalumab, Olaparib Combination Improves Progression-Free Survival in Patients With Advanced Ovarian Cancer

Dual Bispecific Combination Study Shows 96% Overall Response Rate in Relapsed/Refractory Multiple Myeloma

Pharmacy Focus: Independent Rx Forum- What to Know for the NCPA 2022 Annual Convention

PROSPECT Trial Shows De-escalation of Rectal Cancer Treatment Can Achieve Same High Cure Rate With Less Toxicity

Pharmacy Focus: On The Shelf - Camille Schrier, 2019 and 2020 Miss America

Overall Survival of Patients With Metastatic NSCLC Sustained Up to 4 Years With Opdivo, Yervoy Combination

Durvalumab, Olaparib Combination Improves Progression-Free Survival in Patients With Advanced Ovarian Cancer

Dual Bispecific Combination Study Shows 96% Overall Response Rate in Relapsed/Refractory Multiple Myeloma

Pharmacy Focus: Independent Rx Forum- What to Know for the NCPA 2022 Annual Convention

PROSPECT Trial Shows De-escalation of Rectal Cancer Treatment Can Achieve Same High Cure Rate With Less Toxicity

Pharmacy Focus: On The Shelf - Camille Schrier, 2019 and 2020 Miss America

Overall Survival of Patients With Metastatic NSCLC Sustained Up to 4 Years With Opdivo, Yervoy Combination

Durvalumab, Olaparib Combination Improves Progression-Free Survival in Patients With Advanced Ovarian Cancer

Related Content

Multiple Myeloma multiplex leukemia cancer 3d color render illustration closeup.Credit: LASZLO - stock.adobe.com.

Dual Bispecific Combination Study Shows 96% Overall Response Rate in Relapsed/Refractory Multiple Myeloma

Pharmacy Focus: Independent Rx Forum- What to Know for the NCPA 2022 Annual Convention

Pharmacy Focus: Independent Rx Forum- What to Know for the NCPA 2022 Annual Convention

Credit: Robert - stock.adobe.com

PROSPECT Trial Shows De-escalation of Rectal Cancer Treatment Can Achieve Same High Cure Rate With Less Toxicity

Pharmacy Focus: On The Shelf - Camille Schrier, 2019 and 2020 Miss America

Pharmacy Focus: On The Shelf - Camille Schrier, 2019 and 2020 Miss America

Doctor watching a xray of lung cancer on digital tablet. Radiology concept | Image Credit: steph photographies - stock.adobe.com

Overall Survival of Patients With Metastatic NSCLC Sustained Up to 4 Years With Opdivo, Yervoy Combination

Credit: blueringmedia - stock.adobe.com

Durvalumab, Olaparib Combination Improves Progression-Free Survival in Patients With Advanced Ovarian Cancer

Editorial Staff

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.